Show simple item record

dc.contributor.authorKalodimou, Georgia
dc.contributor.authorVeit, Svenja
dc.contributor.authorJany, Sylvia
dc.contributor.authorKalinke, Ulrich
dc.contributor.authorBroder, Christopher C
dc.contributor.authorSutter, Gerd
dc.contributor.authorVolz, Asisa
dc.date.accessioned2020-01-14T13:58:24Z
dc.date.available2020-01-14T13:58:24Z
dc.date.issued2019-12-24
dc.identifier.citationViruses. 2019 Dec 24;12(1). pii: v12010026. doi: 10.3390/v12010026.en_US
dc.identifier.issn1999-4915
dc.identifier.pmid31878180
dc.identifier.doi10.3390/v12010026
dc.identifier.urihttp://hdl.handle.net/10033/622081
dc.description.abstractNipah virus (NiV) is an emerging zoonotic virus that is transmitted by bats to humans and to pigs, causing severe respiratory disease and often fatal encephalitis. Antibodies directed against the NiV-glycoprotein (G) protein are known to play a major role in clearing NiV infection and in providing vaccine-induced protective immunity. More recently, T cells have been also shown to be involved in recovery from NiV infection. So far, relatively little is known about the role of T cell responses and the antigenic targets of NiV-G that are recognized by CD8 T cells. In this study, NiV-G protein served as the target immunogen to activate NiV-specific cellular immune responses. Modified Vaccinia virus Ankara (MVA), a safety-tested strain of vaccinia virus for preclinical and clinical vaccine research, was used for the generation of MVA-NiV-G candidate vaccines expressing different versions of recombinant NiV-G. Overlapping peptides covering the entire NiV-G protein were used to identify major histocompatibility complex class I/II-restricted T cell responses in type I interferon receptor-deficient (IFNAR-/-) mice after vaccination with the MVA-NiV-G candidate vaccines. We have identified an H2-b-restricted nonamer peptide epitope with CD8 T cell antigenicity and a H2-b 15mer with CD4 T cell antigenicity in the NiV-G protein. The identification of this epitope and the availability of the MVA-NiV-G candidate vaccines will help to evaluate NiV-G-specific immune responses and the potential immune correlates of vaccine-mediated protection in the appropriate murine models of NiV-G infection. Of note, a soluble version of NiV-G was advantageous in activating NiV-G-specific cellular immune responses using these peptidesen_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectMVA vector vaccinesen_US
dc.subjectT cell responsesen_US
dc.subjectemerging virusesen_US
dc.subjectvaccinationen_US
dc.titleA Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice.en_US
dc.typeArticleen_US
dc.contributor.departmentTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.en_US
dc.identifier.journalVirusesen_US
refterms.dateFOA2020-01-14T13:58:24Z
dc.source.journaltitleViruses


Files in this item

Thumbnail
Name:
Kalodimou et al.pdf
Size:
2.572Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International